Venus Remedies has joined the league of over 100 globally renowned organisations as a member of the AMR Industry Alliance (AMRIA) in continuation of its commitment to develop solutions to combat the grave public health threat posed by antimicrobial resistance (AMR).

Welcoming Venus Remedies as a new member, Melissa Mitchell, Secretariat Lead of AMR Industry Alliance, said, “We are delighted to have Venus Remedies join our ranks. As an organisation, they lead by example and make commendable efforts to counter the threat of AMR by improving the access of AMR-relevant drugs to third-world countries and encouraging appropriate antibiotic use, along with good stewardship activities. Leading companies in the life science sector, like Venus Remedies, are playing a vital role in the mitigation of AMR and continue to strengthen multi-stakeholder collaborations.”

The AMR Industry Alliance is the largest private sector coalition working towards curbing AMR through a coordinated and multipronged response. Since its inception in 2017, it has been persistently contributing towards sustainable solutions to curb AMR by creating a broad industry momentum and facilitating collaboration between the public and private sectors.  The Alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry. The findings underline continued focus and leadership from the life sciences sector in the fight against AMR and continued cross-sector collaborations, while recommending policy and regulatory changes towards a more sustainable marketplace.

Hailing the membership as an endorsement of the notable work done by Venus Remedies to tackle AMR, Saransh Chaudhary, CEO, Venus Medicine Research Centre (VMRC), said, “ It is an honour to collaborate with the global life sciences industry under the aegis of the AMR Industry Alliance and devise sustainable solutions to AMR. I hope this association will amplify our existing efforts against AMR at a global level by shaping relevant AMR policies and plugging the leaks in the current antibiotic research and manufacturing landscape with focus on access and appropriate use.”